Skip to main content
. Author manuscript; available in PMC: 2023 Mar 1.
Published in final edited form as: J Control Release. 2022 Jan 21;343:518–527. doi: 10.1016/j.jconrel.2022.01.022

Figure 7.

Figure 7.

PBPK model recapitulates PEGylated uricase pharmacokinetics and distribution in (A) PEG-uricase responders with typical clearance of the drug, and (B) PEG-uricase non-responders who exhibit accelerated clearance of PEG-uricase, reported in %ID/kg (1 = 100 %ID/kg). Black closed circles represent PEG-uricase levels approximated by uricase activity measurements from Ref [13], whereas red line represents predictions from the current PBPK model. This data reflects the average PEG-uricase level in plasma sampled from 17 (standard clearance; responder) or 13 (accelerated clearance; transient or non-responder) patients at each time point (2h, 48h, 7d, 14d, 21d). Error bars represent standard deviation. It should be noted that the equipment tolerance from Ref [13] allowed a minimum value equivalent to about 0.02 %ID/kg.